ARTICLE | Company News
NuSirt Biopharma, OWL deal
September 26, 2016 7:00 AM UTC
The companies partnered to develop diagnostic tools for trials of NuSirt’s Phase II candidate NS-0200 in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). The produc...